EMA-EUnetHTA Parallel Consultation
Parallel Consultation between EUnetHTA and the European Medicines Agency
Since July 2017, EUnetHTA and the European Medicines Agency (EMA) have offered Parallel Consultations on evidence generation plans. Parallel Consultations aim to allow medicine developers to obtain feedback from regulators and health technology assessment (HTA) bodies on their development plans to support decision-making on marketing authorisation, health technology assessment, and reimbursement of new medicines at the same time. These consultations can take place before or after the product is made available on the market. The objective is to help generate optimal and robust evidence that satisfies the needs of both regulators and HTA bodies.
This initiative has replaced the Parallel Scientific Advice procedure by EMA and HTA bodies which required medicine developers to contact Member States’ HTA bodies individually.
It also builds on previous initiatives and pilots on HTA-regulatory collaboration led by EMA, EUnetHTA and the European Commission. These include the pilot on regulatory-HTA parallel advice, EUnetHTA’s early dialogue initiative, the SEED project financed by the European Commission, and joint research on levels of alignment between regulators and HTAs in parallel advice.
The procedure is a single gateway for Parallel Consultations with EMA and HTA bodies on their evidence-generation plans.
The main benefits of the parallel consultation procedure include:
Patients/Patient representatives and healthcare professionals also participate in the parallel consultation procedure on a routine basis so that their views and experiences are incorporated into discussions.
Some HTA bodies may charge fees for participating in the Parallel Consultation procedure. The EUnetHTA ED Secretariat can provide information on HTA associated fees.
EMA’s scope and the fees charged for this procedure are the same as for standard scientific advice. For more information, see fees payable to EMA.
EMA and EUnetHTA have published the following documents (all available on this webpage):
All requests for EUnetHTA participation in a Parallel Consultation must be made during the EUnetHTA Open Call for ED requests.
For information on the participation of HTA bodies, please contact the EUnetHTA ED Secretariat.
For information regarding the regulatory aspects, please contact the EMA scientific advice Secretariat.
EUnetHTA Early Dialogue Request Form
Guidance on Parallel Consultation
2020 Timelines Parallel consultation EMA EUnetHTA
Parallel Consultation Briefing Book template
EUnetHTA Procedure Guidance for handling Declaration of Interest (DOI) form
Declaration of Interest (DOI) form
Confidentiality Agreement form
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.